Lawmakers are concerned about background checks of Trump's Cabinet picks as red flags surface
Swinney and Brown at memorial service for ‘giant of a man’ Alex Salmond
Rams at New Orleans Saints: Who has the edge?School district defends decision to ban parents who wore ‘XX’ wristbands at daughters’ game with trans athlete
PESHAWAR, (UrduPoint / Pakistan Point News - 30th Nov, 2024) , , on Saturday visited Press Club to offer condolence to senior journalist Saiful Saifi over the death of his . Upon arrival, he was warmly received by Press Club President Arshad Aziz Malik, General Secretary Irfan Musazai, President of the Khyber Union of Journalists Kashif-ud-Din Syed, and other office bearers. During his , Kundi expressed his heartfelt condolences to Saiful Islam Saifi, praying for the eternal peace of the departed soul, and for the strength and patience of the bereaved . He also prayed for the elevation of her ranks in the afterlife. Later, Kundi while talking to discussed the political situation in the country, especially in , along with the prevailing issues of unrest and other concerns facing the province.When Elon Musk posts to X, his 206 million followers, powerful people including President-elect Donald Trump , and the stock market listen. To date, Musk has posted more than 60,000 times on X, the social media network formerly known as Twitter that he purchased in 2022. For years after Musk joined the platform in 2009, he mainly tweeted memes, jokes, and occasionally about his array of companies . Now, he posts on X daily about politics, the media, and the corporate landscape. As the social media company's CEO, the richest person in the world , and a member of Trump's next administration, even Musk's passing thoughts on X are taken seriously. When he joked about buying the news outlet MSNBC, it prompted a widespread fake claim that one of the network's hosts cried on air in response, even though the company isn't actually for sale. Although it may take Musk only a few seconds to craft his posts on X, they have had real influence over what trends online and the price of assets. Here is a look at the times Musk's words have had immediate impact: More: Supreme Court rejects Elon Musk's appeal in SEC fight over what he can post on X Holiday deals: Shop this season’s top products and sales curated by our editors. Defense companies' stock falls after F-35 criticism In a series of posts last weekend, Musk ridiculed F-35 fighter jets on X. He shared a video of drone swarms with the caption, "Meanwhile, some idiots are still building manned fighter jets like the F-35." Stock prices for American defense contractors, who help manufacture the jets, quickly responded. Lockheed Martin stock declined 3.75% and Northrop Grumman stock fell 2.3%, setting four-month lows for the companies, according to Investor's Business Daily . Dogecoin soars after new department memes After Trump announced Musk would co-lead a new Department of Government Efficiency, or DOGE, the valuation of a cryptocurrency by a similar name soared. Musk hyped up Dogecoin, a meme cryptocurrency often associated with the tech billionaire, on X in the hours surrounding Trump's statement . He posted AI-generated images and memes including the coin's Shiba Inu dog mascot . Five hours before Trump's 6 AM announcement, Dogecoin's market capitalization was nearly $53 billion. CoinMarketCap reported that number rose to $62.8 billion by 10 a.m. the same day. As of this Wednesday afternoon, Dogecoin's market capitalization was sitting at about $59 billion. Tesla stock has long fluctuated based on Musk The Security and Exchange Commission is likely still keeping an eye on Musk's activity on X years after it told him he needs to be more careful about what he posts regarding Tesla, his electric vehicle company. The commission first went after Musk in 2018 when he posted that he was "considering taking Tesla private at $420. Funding secured." At the time, the SEC called his posts that boosted Tesla's stock price "false and misleading." Musk settled with the SEC, agreeing to pay a $20 million fine, step down as chairman, and agree to get a lawyer's approval before posting about Tesla. However, Musk continued to post about the company. When he posted in 2020 that he thought Tesla's stock price was too high, it closed 10% lower than the day prior, landing him in more hot water with the SEC. Etsy shares jump after four words On a Tuesday morning in January 2021, Musk was likely scrolling Etsy. "I kinda love Etsy," he wrote in a post that received 280,000 likes. His four-word comment powered a temporary 8% stock surge for the e-commerce company known for selling vintage and handmade goods. Crypto rise after #bitcoin in bio In the early hours of a Friday morning in 2021, Musk added #bitcoin to his then-Twitter bio on the social platform and posted the message, "In retrospect, it was inevitable." The cryptocurrency Bitcoin soared nearly 20% in response after being relatively stable. The surge inspired a rise in Dogecoin's share price at the time as well, according to CNBC . Reach Rachel Barber at rbarber@usatoday.com and follow her on X @rachelbarber_
Kingsview Wealth Management LLC Sells 3,522 Shares of Vanguard Long-Term Treasury Index ETF (NASDAQ:VGLT)Javon Small scored 31 points to rally West Virginia to an 86-78 overtime upset of No. 3 Gonzaga in the opening round of the Battle 4 Atlantis tournament, Wednesday in Nassau, Bahamas. The Mountaineers (4-1) trailed by 10 points early in the second half and by five in the final minute. But over the final 19 seconds of regulation, Tucker DeVries scored five straight points to send the game to overtime. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
A $70 billion AI data centre industrial park is being proposed for northwestern Alberta, with a well-known Canadian investor attached to the project. On Monday, the Municipal District of Greenview announced it had signed a letter of intent with investor Kevin O’Leary Ventures to purchase and develop thousands of acres of land within the Greenview Industrial Gateway (GIG) just south of Grande Prairie. If the mega industrial park is built, it will be considered the largest of its kind in the world. Wonder Valley, which is planned to roll out in multiple phases, would include building off-grid natural gas and geothermal power infrastructure to support the behemoth AI data centre industrial park. A seemingly AI-generated video promoting the project was posted on the O’Leary Ventures . It depicts hyper-futuristic buildings set in a valley where “technology and nature come together in perfect harmony.” O’Leary Ventures, chaired by Canadian multi-millionaire and former investor Kevin O’Leary, claims the area’s cold-weather climate, skilled labour force, and Alberta’s pro-business policies make the GIG an “ideal site” for the project. “My joint venture team, led by Paul Palandjian, CEO of O’Leary Ventures, and Carl Agren, CEO of HPC and AI Data Centres, has sourced what we believe is the most compelling site in North America to generate and offer 7.5 gigawatts of low-cost power to hyperscalers over the next 5-10 years,” said O’Leary. “With existing permits, proximity to stranded natural gas, pipeline infrastructure, water, and a fibre optic network just a few kilometres away, we will be in the ground and up and running sooner than any scale project of its kind.” The project’s first phase, producing 1.4 gigawatts of power, is projected to cost $2 billion, with annual expansions of 1 gigawatt increments. The total investment, including infrastructure and ancillary structures, is expected to exceed $70 billion over its lifetime. “This is fantastic news for Alberta. Our efforts to attract investment, grow our technology and innovation sector, and leverage our natural and human resources are being noticed. I’m excited to watch this project unfold in the months and years to come,” said Premier Danielle Smith. Plans also include engaging Indigenous communities to create a mutually beneficial relationship. The stated Wonder Valley is expected to attract attention from global investors and industry leaders, setting a “new benchmark” for large-scale data infrastructure projects worldwide. “Beyond jobs and financial benefits, this venture promises to establish Alberta and Canada as world leaders and as a center of excellence in this emerging industry.”
Swinney and Brown at memorial service for ‘giant of a man’ Alex Salmond
NORTH ALABAMA 100, DALTON STATE 69NZME secures exclusive audio partnership with SailGPDiabetic Peripheral Neuropathy Market size in the 7MM was approximately USD 2,740 million in 2022, estimated DelveInsight 11-26-2024 12:42 AM CET | Health & Medicine Press release from: ABNewswire DelveInsight's "Diabetic Peripheral Neuropathy Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Diabetic Peripheral Neuropathy, historical and forecasted epidemiology as well as the Diabetic Peripheral Neuropathy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. Discover Key Insights into the Diabetic Peripheral Neuropathy Market with DelveInsight's In-Depth Report @ Diabetic Peripheral Neuropathy Market Size [ https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Key Takeaways from the Diabetic Peripheral Neuropathy Market Report * In 2023, the highest number of type-specific cases of diabetic neuropathy were observed for peripheral diabetic neuropathy in the 7MM. * The total prevalent cases of diabetic peripheral neuropathy in the 7MM were around 34,000,000 cases in 2023 out of which the highest prevalent cases of this disease were seen in the United States. * Among EU4 and the UK, Germany accounted for the highest cases of the total prevalent cases of diabetic neuropathy, whereas Spain accounted for the least number of cases. * The US accounted for nearly 50% of total treated cases in 2023, which is expected to increase by 2034. * The leading Diabetic Peripheral Neuropathy Companies such as Helixmith, Aptinyx, WinSanTor, Inc., Regenacy Pharmacuticals, Novaremed Ltd., Grunenthal GmbH, Glenmark Pharmaceuticals, and others. * Promising Diabetics Peripheral Neuropathy Therapies such as LY3556050, Engensis, Suzetrigine, Pregabalin , and others. Stay ahead in the Diabetic Peripheral Neuropathy Therapeutics Market with DelveInsight's Strategic Report @ Diabetic Peripheral Neuropathy Market Outlook [ https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Diabetic Peripheral Neuropathy Epidemiology Segmentation in the 7MM * Diabetic Peripheral Neuropathy Prevalent Cases * Diabetic Peripheral Neuropathy Treated Cases * Diabetic Peripheral Neuropathy Prevalent Cases of Painful Download the report to understand which factors are driving Diabetic Peripheral Neuropathy epidemiology trends @ Diabetic Peripheral Neuropathy Prevalence [ https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Diabetic Peripheral Neuropathy Marketed Drugs * QUTENZA (capsaicin): Grunenthal/Averitas Pharma QUTENZA (capsaicin), developed by Grunenthal and Averitas Pharma, is an 8% topical system that contains capsaicin in a localized dermal delivery system. Capsaicin is an agonist for the transient receptor potential vanilloid 1 receptor (TRPV1), which is an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. Topical administration of capsaicin causes an initial enhanced stimulation of the TRPV1-expressing cutaneous nociceptors that may be associated with painful sensations. In July 2020, Grunenthal's US subsidiary Averitas Pharma received US FDA approval for a QUTENZA (capsaicin) 8% patch for treating neuropathic pain associated with Diabetic Peripheral Neuropathy of the feet in adults. * TARLIGE (mirogabalin besylate): Daiichi Sankyo TARLIGE (mirogabalin besylate) is an orally administered gabapentinoid developed by Daiichi Sankyo for the treatment of peripheral neuropathic pain, including diabetic Peripheral Neuropathic pain and postherpetic neuralgia. In January 2019, Daiichi Sankyo announced the approval of TARLIGE for marketing in Japan for the treatment of Diabetic Peripheral Neuropathy and expects the drug to benefit patients in Japan by providing a new therapeutic option for the treatment of Peripheral Neuropathy Pain. Diabetic Peripheral Neuropathy Emerging Drugs * Engensis (VM202): Helixmith Engensis (VM202), developed by Helixmith is a DNA-based drug designed to produce two isoforms of HGF (hepatocyte growth factor), HGF728 and HGF723. When VM202 is delivered to the affected area by a single intramuscular injection, this drug enters a small portion of the surrounding muscle cells. In the case of Diabetic Peripheral Neuropathy, it has the potential to reverse the underlying cause of neuropathy through an angio-neurorestorative effect, without simply managing the pain. This drug is currently in Phase III developmental stage and has been granted RMAT (Regenerative Medicine Advanced Therapy) designation by the US FDA in 2018. * Suzetrigine (VX-548): Vertex Pharmaceuticals VX-548 being developed by Vertex Pharmaceuticals is an oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. NaV1.8 is a genetically validated target for the treatment of pain and multiple pain indications including acute pain, and neuropathic pain. It is currently in Phase III development stage. Get In-Depth Knowledge on Diabetic Peripheral Neuropathy Market Trends and Forecasts with DelveInsight @ Diabetic Peripheral Neuropathy Treatment Market [ https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Diabetic Peripheral Neuropathy Market Outlook Treatment modalities focus on optimized diabetic management and symptomatic relief. Glycemic control is the first step in the approach to disease management and has been shown to improve the occurrence of falls and the presence of foot ulcers. The three main principles of treatment for peripheral neuropathy are glycemic control, foot care, and pain management. The prescription medicines commonly used for managing diabetic peripheral neuropathy pain include Gabapentin and Pregabalin, Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and Opioids. Other Alternatives include Antiseizure Medications like carbamazepine or lamotrigine. Diabetic Peripheral Neuropathy Drugs Uptake Suzetrigine (VX-548), under development by Vertex Pharmaceuticals, holds promise as a potential game-changer in the treatment landscape of diabetic peripheral neuropathy. Positioned as an oral, selective NaV1.8 inhibitor, Suzetrigine boasts high selectivity for NaV1.8 over other NaV channels, enhancing its therapeutic potential. Its Phase III development stage underscores its advancement towards market entry. The oral route of administration offers a distinct advantage, ensuring ease of uptake for patients compared to alternative pipeline drugs. Moreover, Suzetrigine's mechanism of action aligns with addressing neuropathic pain effectively. Unlock Strategic Insights with DelveInsight's Comprehensive Diabetic Peripheral Neuropathy Market Report @ Diabetic Peripheral Neuropathy Market Drivers and Barriers [ https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Scope of the Diabetic Peripheral Neuropathy Market Report * Coverage- 7MM * Diabetic Peripheral Neuropathy Companies- Helixmith, Aptinyx, WinSanTor, Inc., Regenacy Pharmacuticals, Novaremed Ltd., Grunenthal GmbH, Glenmark Pharmaceuticals, and others. * Diabetics Peripheral Neuropathy Therapies- LY3556050, Engensis, Suzetrigine, Pregabalin, and others. * Diabetic Peripheral Neuropathy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies * Diabetic Peripheral Neuropathy Unmet Needs, KOL's views, Analyst's views, Diabetic Peripheral Neuropathy Market Access and Reimbursement Table of Content 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 Diabetic Peripheral Neuropathy Market Overview at a Glance 7 Disease Background and Overview 8 Treatment and Management 9 Epidemiology and Patient Population of Diabetic Peripheral Neuropathy in the 7MM 10 Patient Journey 11 Marketed Therapies Full list of marketed drugs will be provided in the report 12 Emerging Therapies Full list of emerging drugs will be provided in the report 13 Diabetic Peripheral Neuropathy: 7MM Market Analysis 14 Unmet Needs 15 SWOT Analysis 16 KOL Views 17 Market Access and Reimbursement 18 Appendix 19 DelveInsight Capabilities 20 Disclaimer 21 About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=diabetic-peripheral-neuropathy-market-size-in-the-7mm-was-approximately-usd-2740-million-in-2022-estimated-delveinsight ] Phone: 09650213330 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/case-study/in-licensing-opportunity This release was published on openPR.
SFL ( NYSE:SFL – Get Free Report ) was upgraded by investment analysts at Fearnley Fonds from a “hold” rating to a “strong-buy” rating in a research note issued on Thursday, Zacks.com reports. Separately, Pareto Securities raised shares of SFL from a “hold” rating to a “buy” rating in a research note on Tuesday, August 20th. View Our Latest Analysis on SFL SFL Stock Up 1.0 % SFL ( NYSE:SFL – Get Free Report ) last posted its quarterly earnings results on Wednesday, November 6th. The shipping company reported $0.34 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.03). The company had revenue of $255.30 million for the quarter, compared to analyst estimates of $243.98 million. SFL had a return on equity of 14.61% and a net margin of 16.03%. The business’s revenue for the quarter was up 24.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.23 earnings per share. Institutional Trading of SFL A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio acquired a new position in SFL in the 3rd quarter valued at $34,000. Quarry LP grew its position in shares of SFL by 428.2% in the third quarter. Quarry LP now owns 3,967 shares of the shipping company’s stock valued at $46,000 after purchasing an additional 3,216 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in shares of SFL in the third quarter valued at about $49,000. Farther Finance Advisors LLC lifted its position in shares of SFL by 1,375.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,293 shares of the shipping company’s stock worth $50,000 after purchasing an additional 4,002 shares during the last quarter. Finally, Millburn Ridgefield Corp acquired a new position in shares of SFL during the 3rd quarter worth about $92,000. Institutional investors and hedge funds own 28.59% of the company’s stock. SFL Company Profile ( Get Free Report ) SFL Corporation Ltd., a maritime and offshore asset owning and chartering company, engages in the ownership, operation, and chartering out of vessels and offshore related assets on medium and long-term charters. The company operates in various sectors of the maritime, and shipping and offshore industries, including oil transportation, dry bulk shipments, chemical transportation, oil products transportation, container transportation, car transportation, and drilling rigs. Read More Receive News & Ratings for SFL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SFL and related companies with MarketBeat.com's FREE daily email newsletter .Washington visits New Jersey after shootout win
None(The Center Square) – The latest federal numbers show the U.S. deficit is soaring as President Joe Biden heads out of office. The U.S. Congressional Budget Office released its monthly budget review on Monday, which showed that in the first two months of this fiscal year, the federal government has run up a deficit of $622 billion. “That amount is $242 billion more than the deficit recorded during the same period last fiscal year,” CBO said in its report . That figure means the deficit is nearly 40% higher than this time last year. “The most alarming turkey in November was the federal government’s inability to live within its means,” Maya MacGuineas, president of the Committee for a Responsible Federal Budget, said in a statement. “We are only two months into the fiscal year, and we have already borrowed a staggering $622 billion, with $365 billion in the month of November alone." Deficits never surpassed one trillion dollars before the COVID-19 pandemic. Since then, they remain well above one trillion and for this next fiscal year are well beyond the pace to surpass $1 trillion. The deficit last fiscal year was about $1.8 trillion. Billionaire Elon Musk, now an advisor to President-elect Donald Trump, lamented the debt, which is about $36 trillion, on X Monday. “If we don’t fix the deficit, everything will suffer, including essential spending like DoD, Medicare & Social Security,” Musk said. “It’s not optional.” CBO did explain that some of the increase is from accounting changes. From CBO: The change in the deficit was influenced by the timing of outlays and revenues alike. Outlays in October 2023 were reduced by shifts in the timing of certain federal payments that otherwise would have been due on October 1, 2023, which fell on a Sunday. (Those payments were made in September 2023.) Outlays in November 2024 were boosted by the shift to that month of payments due December 1, 2024, a Saturday. If not for those shifts, the deficit thus far in fiscal year 2025 would have been $541 billion, or $88 billion more than the shortfall at this point last year, and outlays would have been $38 billion more.”
Lions rule out Terrion Arnold, put Ennis Rakestraw on IR - NBC Sports
Deficit soars as Biden heads out the doorCDC chief urges focus on health threats as agency confronts political changesNEW YORK (AP) — The outgoing head of the nation’s top public health agency urged the next administration to maintain its focus and funding to keep Americans safe from emerging health threats. “We need to continue to do our global work at CDC to make sure we are stopping outbreaks at their source,” Dr. Mandy Cohen, director of the Centers for Disease Control and Prevention, said in an interview Monday with The Associated Press. “We need to keep that funding up. We need to keep the expertise up. We need to keep the diplomacy up.” Cohen, 46, will be leaving office in January after about 18 months in the job. President-elect Donald Trump on Friday night said he picked Dave Weldon , a former Congressman from Florida, to be the agency’s next chief. Cohen said she hasn’t met Weldon and doesn’t know him. She previously voiced concern about Robert F. Kennedy Jr., the anti-vaccine advocate and CDC critic nominated to oversee all federal public health agencies . The CDC, with a $9.2 billion core budget, is charged with protecting Americans from disease outbreaks and other public health threats. The staff is heavy with scientists — 60% have master’s degrees or doctorates. The last eight years have been perhaps the most difficult in the agency's history. The CDC once enjoyed a sterling international reputation for its expertise on infectious diseases and other causes of illness and death. But trust in the agency fell because of missteps during the early days of the COVID-19 pandemic, political attacks and resistance to infection-prevention measures like wearing masks and getting vaccinated. The CDC has four political appointees, out of about 13,000 employees. The rest serve no matter who is in the White House, with civil service protections against efforts to fire them for political reasons. Trump said during the campaign that he wants to convert many federal agency positions into political appointments, meaning those employees could be hired and fired by whoever wins the election. There’s also a proposal to split the agency in two: one to track disease data, and another focused on public health but with a limited ability to make policy recommendations. And then there’s a current budget proposal in Congress that would cut the agency’s funding by 22%. It would also eliminate the CDC’s National Center for Injury Prevention and Control, which works on topics like drownings, drug overdoses, suicides and and shooting deaths. Cohen said there’s reason to be proud of the agency’s work in recent years. The CDC has built partnerships to improve the availability of testing for different infections and to watch for signs of disease outbreaks by monitoring wastewater . There are emerging threats, as always, but no new, full-fledged public health emergencies, she said. The day after the Nov. 5 election, Cohen emailed CDC employees to urge them to keep going. “While the world may feel different with changes ahead — our mission has not changed,” she wrote. She said she’s not aware of any wave of worried CDC scientists heading for the doors because of the election results. “There is a difference between campaigning and governing,” she said. “I want to go into this in a way that we’re passing the baton.” Cohen said she doesn’t know what she’ll do next, other than spend time with her family in Raleigh, North Carolina, where her family maintained its residence while she ran the agency. Next year, for the first time, the CDC director will be subject to Senate confirmation, which could make for a gap before Trump's pick takes the helm. CDC Deputy Director Dr. Debra Houry has been assigned to help manage the transition. Aside from administration transition, the CDC has to face several looming threats. Officials this month confirmed the first U.S. case of a new form of mpox that was first seen in eastern Congo. There’s also the ongoing stream of bird flu cases , most of them mild illnesses seen in farmworkers who were in direct contact with infected cows or chickens. CDC officials say they believe the risk to the public remains low and that there’s no evidence it’s been spreading between people. “I don’t think we’re yet at a turning place. But does that mean it couldn’t change tomorrow? It could,” she said. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.